Yüklüyor......

Prevention of Bone Loss with Risedronate in Breast Cancer Survivors: A Randomized, Controlled Clinical Trial

PURPOSE: Aromatase inhibitors (AIs), adjuvant endocrine therapy for postmenopausal women with hormone receptor positive breast cancer, are associated with bone loss and fractures. Our objectives were to determine if 1) oral bisphosphonate therapy can prevent bone loss in women on an AI and, 2) early...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Osteoporos Int
Asıl Yazarlar: Greenspan, Susan L., Vujevich, Karen T., Brufsky, Adam, Lembersky, Barry C., van Londen, G.J., Jankowitz, Rachel C., Puhalla, Shannon L., Rastogi, Priya, Perera, Subashan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4766869/
https://ncbi.nlm.nih.gov/pubmed/25792492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-015-3100-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!